IP Library › Granted Patent US 12,239,993
Granted Patent B2
US 12,239,993 · App. 17/273,100 · Granted Mar 4, 2025

Devices and methods for antibiotic susceptibility testing

Inventors: David Swenson (Santa Clara, CA); Phoebe Cao (Sunol, CA); Gary Schoolnik (Washington, DC); Bryan D. Knysh (Santa Clara, CA); Teresa M. Abraham (San Jose, CA)
Assignee: Visby Medical, Inc.
B01L7/525C12Q1/6827C12Q1/689B01L2200/10B01L2200/16B01L2400/0478B01L2400/0644C12Q2600/106C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,239,993
App. No.
17/273,100
Granted
Mar 4, 2025
Kind
B2
Abstract

The disclosure relates generally to molecular diagnostic devices configured to amplifying a single nucleotide polymorphism (SNP) locus and discriminate between two or more allelic variants of the SNP, indicating presence or absence of a target allele. In some embodiments, the molecular diagnostic devices are capable of detecting, at point-of-care, SNPs associated with resistance or susceptibility to antibiotic treatment of bacterial infections. In other aspects, the disclosure provides methods of treatment for disease or disorders (e.g. bacterial infections) where treatment is guided by presence or absence of an allele at a SNP locus as determined by such molecular diagnostic devices.

Claims (31)

1. A molecular diagnostic device, comprising:

a sample preparation module configured to receive a biological sample, wherein the biological sample comprises a polynucleotide;

a reagent module containing a primer set targeting a single nucleotide polymorphism (SNP) locus in the polynucleotide;

an amplification module including a reaction volume and a heater, the reaction volume configured to receive the biological sample and an amplification solution comprising the primer set, the heater configured to convey thermal energy into the reaction volume to amplify the polynucleotide to produce an output containing a target amplicon comprising the SNP locus; and

a detection module configured to receive the target amplicon, the detection module including a probe designed to bind to the SNP locus of the target amplicon if the SNP locus comprises a target allele, while minimizing binding to the SNP locus of the target amplicon if the SNP locus comprises an alternative allele,

wherein the target allele is a drug-resistance allele, and the molecular diagnostic device specifically detects the drug-resistance allele in the biological sample.

2. The molecular diagnostic device of claim 1 , wherein the primer set is designed to flank the SNP locus.

3. The molecular diagnostic device of claim 1 , wherein the primer set targeting the SNP locus comprises:

i) an upstream oligonucleotide primer substantially complementary to an upstream primer binding site at the 5′ terminus of the target region on the antisense strand; and

ii) a downstream oligonucleotide primer substantially complementary to a downstream primer binding site at the 3′ terminus of the target region on the sense strand.

4. The molecular diagnostic device of claim 1 , wherein the molecular diagnostic device comprises a temperature controller configured to maintain the temperature of the detection module at about 10° C. less than the melting temperature of the probe.

5. The molecular diagnostic device of claim 1 , wherein the probe comprises at most two nucleotide mismatches to the probe binding site.

6. The molecular diagnostic device of claim 1 , wherein the probe is perfectly complementary to the probe binding site.

7. The molecular diagnostic device of claim 1 , wherein the detection module comprises a second probe substantially complementary to a second probe binding site, wherein the second probe binding site does not comprise the SNP locus.

8. The molecular diagnostic device of claim 7 , wherein the second probe comprises between 12 and 25 nucleotides.

9. The molecular diagnostic device of claim 7 , wherein the second probe has a melting temperature of between 50° C. and 60° C.

10. The molecular diagnostic device of claim 7 , wherein the second probe comprises a sequence selected from any one of SEQ ID NO: 6 or 22.

11. The molecular diagnostic device of claim 1 , wherein the alternative allele is a drug-sensitivity allele.

12. The molecular diagnostic device of claim 1 , wherein the SNP locus is within a gyrA region.

13. The molecular diagnostic device of claim 1 , wherein the primer set is designed to flank the gyrA 91 locus.

14. The molecular diagnostic device of claim 1 , wherein the probe is designed to maximize binding to the wild type, ciprofloxacin-sensitive gyrA Ser-91 genotype while minimizing binding to other SNPs at a gyrA Ser-91 site that confers a drug resistance.

15. The molecular diagnostic device of claim 1 , wherein the probe is substantially complementary to a probe binding site comprising the codon encoding gyrA Ser-91, and wherein the probe comprises a nucleotide that matches an allele encoding ciprofloxacin-sensitive gyrA Ser-91 genotype.

16. The molecular diagnostic device of claim 1 , wherein the probe discriminates between an allele encoding the ciprofloxacin-sensitive gyrA Ser-91 genotype and the antiallele encoding the gyrA Phe-91 site that confers resistance to ciprofloxacin.

17. The molecular diagnostic device of claim 1 , wherein the probe is characterized by a thermodynamic fulcrum of about 52° C.

18. The molecular diagnostic device of claim 1 , wherein the probe comprises a sequence selected from any one of SEQ ID NO: 14-20.

19. The molecular diagnostic device of claim 1 , wherein the molecular diagnostic device determines whether a subject suspected of having a drug-sensitive bacterial infection has a drug-sensitive bacterial infection.

20. The molecular diagnostic device of claim 1 , wherein the molecular diagnostic device determines whether a subject suspected of having a drug-resistant bacterial infection has a drug-resistant bacterial infection.

21. A method, comprising:

a) introducing into the molecular diagnostic device of claim 1 a biological sample from a subject having or suspected of having a disease or disorder characterized by one or more SNPs associated with susceptibility to a treatment, wherein the biological sample comprising a polynucleotide from the subject,

b) administering the treatment if the molecular diagnostic device indicates the polynucleotide comprises a SNP locus comprising an allele associated with susceptibility to the treatment.

22. The method of claim 21 , wherein the disease or disorder is a bacterial infection.

Assignments (2)
SECURITY INTEREST Recorded Mar 7, 2025
From: VISBY MEDICAL, INC.
To: ANKURA TRUST COMPANY, LLC
Reel/Frame 070442/0884 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2021
From: SWENSON, DAVID; CAO, PHOEBE; SCHOOLNIK, GARY; KNYSH, BRYAN D.; ABRAHAM, TERESA M.
To: VISBY MEDICAL, INC.
Reel/Frame 055570/0463 →
Continuity (3)
Provisional Application 62820359 · Mar 19, 2019
Provisional Application 62726379 · Sep 3, 2018
Related Publication 20210299669A1 · Sep 30, 2021
References Cited (345)
US 4789630A · Bloch et al. · 1988 [cited by applicant]
US 5229297A · Schnipelsky et al. · 1993 [cited by applicant]
US 5498392A · Wilding et al. · 1996 [cited by applicant]
US 5726026A · Wilding et al. · 1998 [cited by applicant]
US 5882903A · Andrevski et al. · 1999 [cited by applicant]
US 5922591A · Anderson et al. · 1999 [cited by applicant]
US 6153425A · Kozwich et al. · 2000 [cited by applicant]
US 6235479B1 · Rogers · 2001 [cited by applicant]
US 6369893B1 · Christel et al. · 2002 [cited by applicant]
US 6374684B1 · Dority · 2002 [cited by applicant]
US 6610499B1 · Fulwyler et al. · 2003 [cited by applicant]
US 6645758B1 · Schnipelsky et al. · 2003 [cited by applicant]
US 6780617B2 · Chen · 2004 [cited by applicant]
US 6821771B2 · Festoc · 2004 [cited by applicant]
US 6893879B2 · Petersen et al. · 2005 [cited by applicant]
US 7189522B2 · Esfandiari · 2007 [cited by applicant]
US 7297313B1 · Northrup et al. · 2007 [cited by applicant]
US 7384782B2 · Nakatani et al. · 2008 [cited by applicant]
US 7416892B2 · Battrell et al. · 2008 [cited by applicant]
US 7553675B2 · Jerome et al. · 2009 [cited by applicant]
US 7569382B2 · Li · 2009 [cited by applicant]
US 7579172B2 · Cho et al. · 2009 [cited by applicant]
US 7592139B2 · West et al. · 2009 [cited by applicant]
US 7648835B2 · Breidford et al. · 2010 [cited by applicant]
US 7705339B2 · Smith et al. · 2010 [cited by applicant]
US 7754452B2 · Kim et al. · 2010 [cited by applicant]
US 7767439B2 · Oh et al. · 2010 [cited by applicant]
US 7799521B2 · Chen et al. · 2010 [cited by applicant]
US 7914986B2 · Nunn · 2011 [cited by applicant]
US 7985716B2 · Yershov et al. · 2011 [cited by applicant]
US 7998757B2 · Darrigrand et al. · 2011 [cited by applicant]
US 8018593B2 · Tan et al. · 2011 [cited by applicant]
US 8048386B2 · Dority et al. · 2011 [cited by applicant]
US 8088616B2 · Handique · 2012 [cited by applicant]
US 8110392B2 · Battrell et al. · 2012 [cited by applicant]
US 8133671B2 · Williams et al. · 2012 [cited by applicant]
US 8133703B2 · Ching et al. · 2012 [cited by applicant]
US 8163535B2 · Reed et al. · 2012 [cited by applicant]
US 8169610B2 · Oldham et al. · 2012 [cited by applicant]
US 8187557B2 · Van Atta et al. · 2012 [cited by applicant]
US 8216832B2 · Battrell et al. · 2012 [cited by applicant]
US 8232091B2 · Maltezos et al. · 2012 [cited by applicant]
US 8232094B2 · Hasson et al. · 2012 [cited by applicant]
US 8298763B2 · Regan · 2012 [cited by applicant]
US 8329453B2 · Battrell et al. · 2012 [cited by applicant]
US 8343442B2 · McBride et al. · 2013 [cited by applicant]
US 8343754B2 · Wittwer et al. · 2013 [cited by applicant]
US 8372340B2 · Bird et al. · 2013 [cited by applicant]
US 8389960B2 · Pieprzyk et al. · 2013 [cited by applicant]
US 8394608B2 · Ririe et al. · 2013 [cited by applicant]
US 8426134B2 · Piepenburg et al. · 2013 [cited by applicant]
US 8492136B2 · Carlisle et al. · 2013 [cited by applicant]
US 8557518B2 · Jovanovich et al. · 2013 [cited by applicant]
US 8637250B2 · Jenison · 2014 [cited by applicant]
US 8722426B2 · Lambotte et al. · 2014 [cited by applicant]
US 8728765B2 · Ching et al. · 2014 [cited by applicant]
US 8765367B2 · Breidenthal et al. · 2014 [cited by applicant]
US 8765454B2 · Zhou et al. · 2014 [cited by applicant]
US 8772017B2 · Battrell et al. · 2014 [cited by applicant]
US 8795592B2 · Eiriksson · 2014 [cited by applicant]
US 8894946B2 · Nielsen et al. · 2014 [cited by applicant]
US 8895255B1 · Goldberg et al. · 2014 [cited by applicant]
US 8900828B2 · Smith et al. · 2014 [cited by applicant]
US 8911941B2 · Michlitsch · 2014 [cited by applicant]
US 8911949B2 · Bertrand et al. · 2014 [cited by applicant]
US 8916375B2 · Landers et al. · 2014 [cited by applicant]
US 8945843B2 · Alvino et al. · 2015 [cited by applicant]
US 8975027B2 · Gale et al. · 2015 [cited by applicant]
US 8980561B1 · Cai et al. · 2015 [cited by applicant]
US 9012236B2 · Jovanovich et al. · 2015 [cited by applicant]
US 9023639B2 · Kim et al. · 2015 [cited by applicant]
US 9034168B2 · Khattak et al. · 2015 [cited by applicant]
US 9044729B2 · Rengifo et al. · 2015 [cited by applicant]
US 9150907B2 · Shaikh et al. · 2015 [cited by applicant]
US 9207236B2 · Cary · 2015 [cited by applicant]
US 9238833B2 · Chen et al. · 2016 [cited by applicant]
US 9260750B2 · Hillebrand et al. · 2016 [cited by applicant]
US 9387478B2 · Bergstedt et al. · 2016 [cited by applicant]
US 9428781B2 · Cai et al. · 2016 [cited by applicant]
US 9453255B2 · Ozawa et al. · 2016 [cited by applicant]
US 9469871B2 · Bearinger et al. · 2016 [cited by applicant]
US 9475049B2 · Siciliano · 2016 [cited by applicant]
US 9623415B2 · Andreyev et al. · 2017 [cited by applicant]
US 9663821B2 · Unger et al. · 2017 [cited by applicant]
US 9718058B2 · Khattak et al. · 2017 [cited by applicant]
US 9725754B2 · Boyle et al. · 2017 [cited by applicant]
US 9752182B2 · Collier et al. · 2017 [cited by applicant]
US 9789483B2 · Khattak et al. · 2017 [cited by applicant]
US 9890415B2 · Stehr et al. · 2018 [cited by applicant]
US 10040069B2 · Moore et al. · 2018 [cited by applicant]
US 10052629B2 · Andreyev et al. · 2018 [cited by applicant]
US 10112196B2 · Andreyev et al. · 2018 [cited by applicant]
US 10112197B2 · Andreyev et al. · 2018 [cited by applicant]
US 10124334B2 · Andreyev et al. · 2018 [cited by applicant]
US 10146909B2 · Dimov et al. · 2018 [cited by applicant]
US 10173182B2 · Tachibana et al. · 2019 [cited by applicant]
US 10195610B2 · Tang et al. · 2019 [cited by applicant]
US 10233483B2 · Talebpour et al. · 2019 [cited by applicant]
US 10603664B2 · Khattak · 2020 [cited by applicant]
US 11080848B2 · Dimov et al. · 2021 [cited by applicant]
US 11162130B2 · Andreyev et al. · 2021 [cited by applicant]
US 11167285B2 · Andreyev et al. · 2021 [cited by applicant]
US 11168354B2 · Andreyev et al. · 2021 [cited by applicant]
US 11273443B2 · Andreyev et al. · 2022 [cited by applicant]
US 20030027203A1 · Fields · 2003 [cited by applicant]
US 20030027244A1 · Colston et al. · 2003 [cited by applicant]
US 20040018502A1 · Makino et al. · 2004 [cited by applicant]
US 20040110141A1 · Pusey et al. · 2004 [cited by applicant]
US 20040209331A1 · Ririe · 2004 [cited by applicant]
US 20050059030A1 · Bao et al. · 2005 [cited by applicant]
US 20050100946A1 · Lipshutz et al. · 2005 [cited by applicant]
US 20050142036A1 · Kim et al. · 2005 [cited by applicant]
US 20050194316A1 · Pourahmadi et al. · 2005 [cited by applicant]
US 20050227275A1 · Jung et al. · 2005 [cited by applicant]
US 20060127924A1 · Hellyer et al. · 2006 [cited by applicant]
US 20060160205A1 · Blackburn et al. · 2006 [cited by applicant]
US 20060177841A1 · Wangh et al. · 2006 [cited by applicant]
US 20060210998A1 · Kettlitz et al. · 2006 [cited by applicant]
US 20060258012A1 · Yang et al. · 2006 [cited by applicant]
US 20070026391A1 · Stoughton et al. · 2007 [cited by applicant]
US 20070036691A1 · Lin et al. · 2007 [cited by applicant]
US 20070042427A1 · Gerdes et al. · 2007 [cited by applicant]
US 20070154922A1 · Collier et al. · 2007 [cited by applicant]
US 20070277251A1 · Wartiovaara et al. · 2007 [cited by applicant]
US 20070292941A1 · Handique et al. · 2007 [cited by applicant]
US 20080038737A1 · Smith et al. · 2008 [cited by applicant]
US 20080050735A1 · Pushnova · 2008 [cited by applicant]
US 20080057572A1 · Petersen et al. · 2008 [cited by applicant]
US 20080113391A1 · Gibbons et al. · 2008 [cited by applicant]
US 20080153078A1 · Braman et al. · 2008 [cited by applicant]
US 20080280285A1 · Chen et al. · 2008 [cited by applicant]
US 20090035780A1 · McCarthy et al. · 2009 [cited by applicant]
US 20090075269A1 · Caplin · 2009 [cited by applicant]
US 20090130745A1 · Williams et al. · 2009 [cited by applicant]
US 20090186344A1 · Farinas · 2009 [cited by applicant]
US 20090215072A1 · McDevitt et al. · 2009 [cited by applicant]
US 20090325276A1 · Battrell et al. · 2009 [cited by applicant]
US 20100003683A1 · Sarofim et al. · 2010 [cited by applicant]
US 20100025242A1 · Pamula · 2010 [cited by applicant]
US 20100035349A1 · Bau et al. · 2010 [cited by applicant]
US 20100075302A1 · Perlin et al. · 2010 [cited by applicant]
US 20100173393A1 · Handique et al. · 2010 [cited by applicant]
US 20100210038A1 · Blatt et al. · 2010 [cited by applicant]
US 20100291536A1 · Viljoen et al. · 2010 [cited by applicant]
US 20100291588A1 · McDevitt et al. · 2010 [cited by applicant]
US 20100297640A1 · Kumar et al. · 2010 [cited by applicant]
US 20110020876A1 · Wilding et al. · 2011 [cited by applicant]
US 20110039303A1 · Janovich et al. · 2011 [cited by applicant]
US 20110160090A1 · Cary · 2011 [cited by applicant]
US 20110203688A1 · Reed et al. · 2011 [cited by applicant]
US 20110253224A1 · Linder et al. · 2011 [cited by applicant]
US 20110275055A1 · Conner · 2011 [cited by applicant]
US 20110308313A1 · Azimi et al. · 2011 [cited by applicant]
US 20110312074A1 · Azimi et al. · 2011 [cited by applicant]
US 20110312666A1 · Azimi et al. · 2011 [cited by applicant]
US 20110312787A1 · Silverbrook et al. · 2011 [cited by applicant]
US 20110312841A1 · Silverbrook et al. · 2011 [cited by applicant]
US 20120021454A1 · Bikker et al. · 2012 [cited by applicant]
US 20120064534A1 · Pipper et al. · 2012 [cited by applicant]
US 20120088294A1 · Sun et al. · 2012 [cited by applicant]
US 20120135511A1 · Battrell et al. · 2012 [cited by applicant]
US 20120141337A1 · Maltezos et al. · 2012 [cited by applicant]
US 20120264114A1 · Wacogne et al. · 2012 [cited by applicant]
US 20120282681A1 · Teixeira et al. · 2012 [cited by applicant]
US 20120282684A1 · Fritchie et al. · 2012 [cited by applicant]
US 20120288897A1 · Ching et al. · 2012 [cited by applicant]
US 20130040296A1 · Tulp et al. · 2013 [cited by applicant]
US 20130053255A1 · Vangbo et al. · 2013 [cited by applicant]
US 20130078736A1 · Grover et al. · 2013 [cited by applicant]
US 20130115712A1 · Yu et al. · 2013 [cited by applicant]
US 20130118900A1 · Reimitz et al. · 2013 [cited by applicant]
US 20130217026A1 · Egan et al. · 2013 [cited by applicant]
US 20130224729A1 · Church et al. · 2013 [cited by applicant]
US 20130295570A1 · Wangh et al. · 2013 [cited by applicant]
US 20140045191A1 · DeJohn et al. · 2014 [cited by applicant]
US 20140073013A1 · Gorman et al. · 2014 [cited by applicant]
US 20140087359A1 · Njoroge et al. · 2014 [cited by applicant]
US 20140274770A1 · Pack · 2014 [cited by applicant]
US 20140329301A1 · Handique · 2014 [cited by applicant]
US 20140342356A1 · Stender et al. · 2014 [cited by applicant]
US 20150258273A1 · Payne et al. · 2015 [cited by applicant]
US 20150290639A1 · Evtodienko · 2015 [cited by applicant]
US 20150322483A1 · Nakamura et al. · 2015 [cited by applicant]
US 20150346097A1 · Battrell et al. · 2015 [cited by applicant]
US 20160008811A1 · Aser et al. · 2016 [cited by applicant]
US 20160077015A1 · Holmes et al. · 2016 [cited by applicant]
US 20160186240A1 · Andreyev · 2016 [cited by examiner]
US 20160222442A1 · Cary · 2016 [cited by applicant]
US 20160251702A1 · Chattopadhyay et al. · 2016 [cited by applicant]
US 20160256870A1 · Ismagilov et al. · 2016 [cited by applicant]
US 20160281149A1 · Hassibi et al. · 2016 [cited by applicant]
US 20160289669A1 · Fan et al. · 2016 [cited by applicant]
US 20160310948A1 · Nowakowski et al. · 2016 [cited by applicant]
US 20170021356A1 · Dority et al. · 2017 [cited by applicant]
US 20170058324A1 · Balog et al. · 2017 [cited by applicant]
US 20170121756A1 · Abate et al. · 2017 [cited by applicant]
US 20170152510A1 · Lorenz · 2017 [cited by applicant]
US 20170173585A1 · Mahony et al. · 2017 [cited by applicant]
US 20170247745A1 · Schultz et al. · 2017 [cited by applicant]
US 20170260570A1 · Balashov et al. · 2017 [cited by applicant]
US 20170304829A1 · Andreyev et al. · 2017 [cited by applicant]
US 20180135108A1 · Etchebarne · 2018 [cited by applicant]
US 20180135110A1 · Saxena et al. · 2018 [cited by applicant]
US 20180304260A1 · Thomas et al. · 2018 [cited by applicant]
US 20180355410A1 · Lee et al. · 2018 [cited by applicant]
US 20190022643A1 · Andreyev et al. · 2019 [cited by applicant]
US 20190030532A1 · Andreyev et al. · 2019 [cited by applicant]
US 20190032104A1 · Lowery et al. · 2019 [cited by applicant]
US 20190040451A1 · Mahony et al. · 2019 [cited by applicant]
US 20190060895A1 · Myers, III et al. · 2019 [cited by applicant]
US 20190083975A1 · Mitra et al. · 2019 [cited by applicant]
US 20190094114A1 · Myers, III et al. · 2019 [cited by applicant]
US 20190136226A1 · Swenson et al. · 2019 [cited by applicant]
US 20190151844A1 · Andreyev et al. · 2019 [cited by applicant]
US 20190169677A1 · Andreyev et al. · 2019 [cited by applicant]
US 20190193077A1 · Andreyev et al. · 2019 [cited by applicant]
US 20190232283A1 · Andreyev et al. · 2019 [cited by applicant]
US 20190232293A1 · Tang et al. · 2019 [cited by applicant]
US 20190262827A1 · Lalonde et al. · 2019 [cited by applicant]
US 20200086324A1 · Swenson et al. · 2020 [cited by applicant]
US 20200346213A1 · Andreyev et al. · 2020 [cited by applicant]
US 20200406256A1 · Andreyev et al. · 2020 [cited by applicant]
US 20200406257A1 · Andreyev et al. · 2020 [cited by applicant]
US 20200408750A1 · Khattak · 2020 [cited by applicant]
US 20210039097A1 · Andreyev et al. · 2021 [cited by applicant]
US 20210071236A1 · Andreyev et al. · 2021 [cited by applicant]
US 20210207194A1 · Ciopyk et al. · 2021 [cited by applicant]
US 20220055032A1 · Andreyev et al. · 2022 [cited by applicant]
US 20220186208A1 · Swenson et al. · 2022 [cited by applicant]
US 20220203365A1 · Abraham et al. · 2022 [cited by applicant]
US 20220325363A1 · Broughton et al. · 2022 [cited by applicant]
CN 103820439A · 2014 [cited by applicant]
CN 108884489A · 2018 [cited by applicant]
EP 2682480A1 · 2014 [cited by applicant]
KR 20120044060 · 2012 [cited by examiner]
WO WO0118017A1 · 2001 [cited by applicant]
WO WO2001049416A1 · 2001 [cited by applicant]
WO WO2007061943 · 2007 [cited by applicant]
WO WO2008082432 · 2008 [cited by applicant]
WO WO2008149111 · 2008 [cited by applicant]
WO WO2012009813 · 2012 [cited by applicant]
WO WO2014144548A2 · 2014 [cited by applicant]
WO WO2015035260A1 · 2015 [cited by applicant]
WO WO2015164770A1 · 2015 [cited by applicant]
WO WO2016086305A1 · 2016 [cited by applicant]
WO WO2016106391A1 · 2016 [cited by applicant]
WO WO2016203019A1 · 2016 [cited by applicant]
WO WO2017090043A1 · 2017 [cited by applicant]
WO WO2017151195 · 2017 [cited by applicant]
WO WO2017160840A1 · 2017 [cited by applicant]
WO WO2018087205A1 · 2018 [cited by applicant]
WO WO2018119443 · 2018 [cited by applicant]
WO WO2020180858 · 2020 [cited by applicant]
WO WO2020214557 · 2020 [cited by applicant]
WO WO2020223257 · 2020 [cited by applicant]
Huang (Microarrays 4.4 (2015): 570-595) (Year: 2015). [cited by examiner]
Office Action for U.S. Appl. No. 17/139,451, mailed May 4, 2021, 7 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US20/67642, mailed May 3, 2021, 17 pages. [cited by applicant]
Examination Report No. 1 for AU Application No. 2019337088, mailed Oct. 15, 2021, 4 pages. [cited by applicant]
Benett, William et al. “Handheld advanced nucleic acid analyzer,” Event: Environmental and Industrial Sensing, Boston, MA, Proceedings of SPIE, vol. 4200 (2000), pp. 55-63. [cited by applicant]
Edouard et al., “Cost-Effective Pooling of DNA from Nasopharyngeal Swab Samples for Large-Scale Detection of Bacteria by Real-Time PCR,” Journal of Clinical Microbiology, vol. 53, No. 3, Mar. 2015, pp. 1002-1004. [cited by applicant]
Elnifro, Elfath M. et al. “Multiplex PCR: Optimization and Application in Diagnostic Virology,” Clinical Microbiology Reviews, vol. 13, No. 4, Oct. 2000, pp. 559-570. [cited by applicant]
Hassibi et al. “An array-based melt curve analysis method for the identification and classification of closely related pathogen strains.” Biology Methods and Protocols 2018; pp. 1-12. [cited by applicant]
Kim, Young Ho et al., “Performance evaluation of thermal cyclers for PCR in a rapid cycling condition,” BioTechniques, www.biotechniques.com, vol. 44, No. 4, 2008, pp. 495-505. [cited by applicant]
Primiceri, Elisabetta et al. “Key Enabling Technologies for Point-of-Care Diagnostics,” MDPI, Sensors 18, 3607; doi:10.3390/s18113607, www.mdpi.com/journal/sensors, 2018, pp. 1-34. [cited by applicant]
Richards, James et al. “Miniaturized detection system for handheld PCR assays,” Event: Environmental and Industrial Sensing, Boston, MA, Proceedings of SPIE, vol. 4200 (2000), pp. 64-73. [cited by applicant]
Rybicki et al., “Standard PCR Protocol,” Feb. 1, 2001, 4 pages. [cited by applicant]
Terhes et al. “Comparison of a Rapid Molecular Method, the BD GeneOhm Cdiff Assay, to the Most Frequently Used Laboratory Tests for Detection of Toxin-Producing Clostridium difficile in Diarrheal Feces,” Journal of Clin… [cited by applicant]
Tsaloglou, Maria-Nefeli et al. “Handheld isothermal amplification and electrochemical detection of DNA in resource-limited settings,” Analytical Biochemistry 543, 2018, pp. 116-121. [cited by applicant]
Ullerich, Lars et al. “Ultra-fast PCR technologies for point-of-care testing,” De Gruyter, J. Lab Med 2017; 41(5), pp. 239-244. [cited by applicant]
Yotoriyama, T. et al. “Miniaturized PCR Device for Rapid Detection of Infectious Agents,” 14th International Conference on Miniaturized Systems for Chemistry and Life Sciences, Oct. 3-17, 2010, pp. 142-144. [cited by applicant]
White, Adam K. et al. High-throughput microfluidic single-cell RT-qPCR, PNAS, Aug. 23, 2011, vol. 108, No. 34, pp. 13999-14004. [cited by applicant]
White, Adam K. et al. “High-throughput microfluidic single-cell RT-qPCR, Supporting Information White et al. 10.1073/pnas.1019446108” PNAS, Aug. 23, 2011, vol. 108, No. 34, pp. 1-9. [cited by applicant]
Zhang, Chunsun et al. “PCR microfluidic devices for DNA amplification,” Biotechnology Advances 24, (2006) pp. 243-284. [cited by applicant]
Australian Patent Office, 2nd Examination Report for AU2019337088, Apr. 6, 2022, 3 pages. [cited by applicant]
Chinese Patent Office, First Office Action for CN2019800714356, Apr. 27, 2022, 12 pages. [cited by applicant]
European Patent Office, Extended European Search Report for 19856734.9, Jun. 29, 2022, 11 pages. [cited by applicant]
Oleastro, et al., Real-Time PCR Assay for Rapid and Accurate Detection of Point Mutations Conferring Resistance to Clarithromycin in Helicobacter pylori, Journal of Clinical Microbiology, vol. 41, No. 1, Jan. 2003, pp. … [cited by applicant]
Rajendran, et al., Smartphone detection of antibiotic resistance using convective PCR and a lateral flow assay, Sensors and Actuators B: Chemical, Nov. 2019, 10 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2019/049385, mailed Nov. 15, 2019, 12 pages. [cited by applicant]
Extended European Search Report for European Application No. 17821297.3, mailed Dec. 17, 2019, 21 pages. [cited by applicant]
Ahrberg, Christian D. et al. “Polymerase chain reaction in microfluidic devices,” © The Royal Society of Chemistry 2016, Lab Chip, 16, pp. 3866-3884, 20 pgs. [cited by applicant]
Brunklaus, S. et al., Fast nucleic acid amplification for integration in point-of-care applications, Electrophoresis, 2012, vol. 33, pp. 3222-3228. [cited by applicant]
Choi, Gihoon et al., “A field-deployable mobile molecular diagnostic system for malaria at the point of need,” Lab on a Chip, Royal Society of Chemistry, 2016, 16, 4341-4349. [cited by applicant]
Dutta, Gorachand et al. “Microfluidic Devices for Label-Free DNA Detection,” Chemosensors, Sep. 25, 2018, 6, 43 www.mdpi.com/journal/chemosensors, 20 pgs. [cited by applicant]
Gehring et al. “A High-Throughput, Precipitating Colorimetric Sandwich ELISA Microarray for Shiga Toxins,” J. Toxins, vol. 6, p. 1855-72, Jun. 11, 2014. [cited by applicant]
Harding-Esch et al. “A 30-min nucleic acid amplification point-of-care test for genital [cited by applicant]
Huang et al., “Efficient SNP Discovery by Combining Microarray and Lab-on-a-Chip Data for Animal Breeding and Selection,” Microarrays, Nov. 16, 2015, vol. 4, No. 4, pp. 570-595, entire document. [cited by applicant]
Hwang et al., “Black Printed Circuit Board-based Micro-Polymerase Chain Reaction Chip Structure for Fluorescence Detection Test”, International Journal of Control and Automation (2015); vol. 8, No. 10: pp. 15-24 (10 pag… [cited by applicant]
Interbiotech, “Enzymatic substrates for ImmunoAssays,” [retreived from the Internet Nov. 18, 2017: <http://www.interchim.fr/ft/B/BA357a.pdf>], 10 pages. [cited by applicant]
Kim, Yong Tae et al. “Integrated Microdevice of reverse transcription-polymerase chain reaction with colorimetric immunochromatographic detection for rapid gene expression analysis of influenza A H1N1 virus,” Biosensors… [cited by applicant]
Kim, Jungkyu et al. “Automated microfluidic DNA/RNA extraction with both disposable and reusable components,” Journal of Micromechanics and Microengineering, vol. 22, No. 1, Dec. 20, 2011, 21 pages. [cited by applicant]
Kopp et al., “Chemical Amplification: Continuous-Flow PCR on a Chip”, Science (1998); 280 (5366): 1046-1048. [cited by applicant]
Lee et al. “A polymer lab-on-a-chip for reverse transcription (RT)-PCR based point-of-care clinical diagnostics,” The Royal Society of Chemistry, vol. 8, pp. 2121-2127, Oct. 31, 2008. [cited by applicant]
Lee et al. “Single-channel multiplexing without melting curve analysis in real-time PCR,” Scientific Reports, Dec. 11, 2014, vol. 4, Art. No. 7439, pp. 1-6, entire document. [cited by applicant]
Mohammed et al., Modeling of Serpentine Continuous Flow Polymerase Chain Reaction Microfluidics, IJEST, vol. 4, No. 3, pp. 1183-1189, Mar. 2012. [cited by applicant]
Petralia, Salvatore et al. “PCR Technologies for Point of Care Testing: Progress and Perspectives,” ACS Sensors, 2017, 2 (7), pp. 876-891, Jul. 6, 2017. [cited by applicant]
Poritz, Mark A. et al., “FilmArray, an Automated Nested Multiplex PCR System for Multi-Pathogen Detection: Development and Application to Respiratory Tract Infection,” PLoS ONE www.plosone.org, Oct. 2011, vol. 6, Issue … [cited by applicant]
Roskos, Kristina et al. “Simple System for Isothermal DNA Amplification Coupled to Lateral Flow Detection,” PLoS ONE 8(7): e69355. https://doi.org/10.1371/journal.pone.0069355; Jul. 26, 2013, 11 pages. [cited by applicant]
Shafagati, et al., The Use of Nano Trap Particles as a Sample Enrichment Method to Enhance the Detection of Rift Valley Fever Virus. PLOS Neglected Tropical Diseases, Jul. 4, 2013; 7(7): e2296. [cited by applicant]
Tanriverdi et al. A rapid and automated sample-to-result HIV load test for near-patient application. J Infect Dis., 201 Suppl 1:S52-S58, 2010. [cited by applicant]
Thiha et al. A Colorimetric Enzyme-Linked Immunoabsorbent Assay (ELISA) Detection Platform for a Point-Of-Care Dengue Detection System on a Lab-on-Compact-Disc; Sensors ISSN 1424-8220, May 18, 2015. [cited by applicant]
Wu, Jinbo et al. “Extraction, amplification and detection of DNA in microfluidic chip-based assays,” © Springer-Verlag Wein 2013, pp. 1611-1631. [cited by applicant]
Zhang, Chunsun et al. “Survey and Summary—Miniaturized PCR chips for nucleic acid amplification and analysis: latest advances and future trends,” Nucleic Acids Research, 2007, vol. 35, No. 13, pp. 4223-4237. [cited by applicant]
Zumla, Alimuddin et al., “Emerging respiratory tract infections 4—Rapid point of care diagnostic tests for viral and bacterial respiratory tract infections—needs, advances, and future prospects,” Lancet Infect. Dis. www… [cited by applicant]
Public Health Enland. “Update on investigation of UK case of Neisseria gonorrhoeae with high-level resistance to azithromycin and resistance to ceftriaxone acquired abroad,” Health Protection Report, vol. 12, No. 14 (Ap… [cited by applicant]
Hermarajata, P. et al. “Performance and Verification of a Real-Time PCR Assay Targeting the gyrA Gene for Prediction of Ciprofloxacin Resistance in Neisseria ghonrrhoeae,” J. Clinical Microbiology vol. 54, No. 3: 805-80… [cited by applicant]
Allan-Blitz, L. et al. “Ciprofloxacin May be Efficacious in Treating Wild-Type Gyrase A Genotype Neisseria gonorrhoeae Infections,” Sexually Transmitted Diseases, vol. 45, Issue 4, p. e18 (Apr. 2018). [cited by applicant]
Wong, L.K. et al. “Real-Time PCR Targeting the penA Mosaic XXXIV Type for Prediction of Extended-Spectrum-Cephalosporin Susceptibility in Clinical Neisseria gonorrhoeae Isolates,” Am. Society for Microbiology, Antimicro… [cited by applicant]
Buono, S. et al. “Stemming the tide of drug-resistant Neisseria gonorrhoeae: the need for an individualized approach to treatment,” J. Antimicrobial Chemotherapy, vol. 70, pp. 374-381 (Oct. 19, 2014). [cited by applicant]
Kerremans, J. et al. “Rapid identification and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogen-directed antibiotic use,” J. Antimicrobial Chemotherapy, vol. 61, pp. 428-435 (Dec. 21, 2… [cited by applicant]
Tuite, A. et al. “Impact of Rapid Susceptibility Testing and Antibiotic Selection Strategy on the Emergence and Spread of Antibiotic Resistance in Gonorrhea,” J. Infectious Diseases, 216:1141-9 (Nov. 1, 2017). [cited by applicant]
Herbst De Cortina, S. et al. “A Systematic Review of Point of Care Testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis,” Infectious Diseases in Obstetrics and Gynecology, vol. 2016, 17 pa… [cited by applicant]
Huppert, J. et al. “What's the Point? How Point-of-Care STI Tests can Impact Infected Patients,” National Institutes of Health, vol. 9(1): pp. 36-46 (Mar. 1, 2010). [cited by applicant]
Allan-Blitz, L. et al. “Wild-Type Gyrase A Genotype of Neisseria gonorrhoeae Predicts In Vitro Susceptibility to Ciprofloxacin: A Systematic Review of the Literature and Meta-Analysis,” Sex Transm Dis. 44(5): 261-265 (M… [cited by applicant]
Fifer et al. “Sustained transmission of high-level azithromycin-resistant Neisseria gonorrhoeae in England: an observational study,” Lancet Infect Dis 2018; 18: 573-81 (Mar. 6, 2018). [cited by applicant]
Grad, Y. et al. “Genomic Epidemiology of Gonococcal Resistance to Extended-Spectrum Cephalosporins, Macrolides, and Fluoroquinolones in the United States, 2000-2013,” Journal of Infectious Diseases, 214: 1579-87 (2016). [cited by applicant]
Grad, Y. et al. “Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study,” Lancet Infect Dis 14: 220-26 (Jan. 22, 2014). [cited by applicant]
Mortimer, T. et al. “Applications of genomics to slow the spread of multidrug-resistant Neisseria gonorrhoeae,” Annals of the New York Academy of Sciences, Special Issue: Antimicrobial Therapeutics Reviews; 1-17 (2018). [cited by applicant]
Unemo, M. et al. “High In Vitro Susceptibility to the Novel Spiropyrimidinetrione ETX0914 (AZD0914) among 873 Contemporary Clinical Neisseria gonorrhoeae Isolates from 21 European Countries from 2012 to 2014,” Antimicro… [cited by applicant]
Alm, R. et al. “Characterization of the Novel DNA Gyrase Inhibitor AZD0914: Low Resistance Potential and Lack of Cross-Resistance in Neisseria gonorrhoeae,” Antimicrobial Agents and Chemotherapy, vol. 59, No. 3, pp. 147… [cited by applicant]
Lindberg, R. et al. “Neisseria gonorrhoeae Isolates with Reduced Susceptibility to Cefixime and Ceftriaxone: Association with Genetic Polymorphisms in penA, mtrR, porB1b, and ponA,” Antimicrobial Agents and Chemotherapy… [cited by applicant]
Dillard, J. “Genetic Manipulation of Neisseria gonorrhoeae,” Curr Protoc Microbiol, Author Manuscript, 34 pgs (Nov. 2011). [cited by applicant]
Dize, L. et al. “Comparison of self-obtained penile-meatal swabs to urine for the detection of C. trachomatis, N. gonorrhoeae and T. vaginalis,” Sex Transm Infect. 89(4): 305-307 (Jun. 2013). [cited by applicant]
Ng, L. et al. “Mutation in 23S rRNA Associated with Macrolide Resistance in Neisseria gonorrhoeae,” Antimicrobial Agents and Chemotherapy, vol. 46, No. 9, pp. 3020-3025 (Sep. 2002). [cited by applicant]
Allan-Blitz, L. et al. “Implementation of a Rapid Genotypic Assay to Promote Targeted Ciprofloxacin Therapy of Neisseria gonorrhoeae in a Large Health System,” Clinical Infectious Diseases, 64(9): 1268-70 (May 2017). [cited by applicant]
Dona, V. et al. “Multiplex Real-Time PCR Assay with High-Resolution Melting Analysis for Characterization of Antimicrobial Resistance in Neisseria gonorrhoeae,” Journal of Clinical Microbiology, vol. 54, No. 8, pp. 2074… [cited by applicant]
Pond, M. et al. “Accurate detection of Neisseria gonorrhoeae ciprofloxacin susceptibility directly from genital and extragenital clinical samples: towards genotype-guided antimicrobial therapy,” Journal of Antimicrobial… [cited by applicant]
Buckley, C. et al. “Real-time PCR detection of Neisseria gonorrhoeae susceptibility to penicillin,” Journal of Antimicrobial Chemotherapy, 71: 3090-3095 (Jul. 25, 2016). [cited by applicant]
Peterson, S. et al. “Molecular Assay for Detection of Genetic Markers Associated with Decreased Susceptibility to Cephalosporins in Neisseria gonorrhoeae,” Journal of Clinical Microbiology, vol. 53, No. 7, pp. 2042-2048… [cited by applicant]
Vernel-Pauillac, F. et al. “Quinolone Resistance in Neisseria gonorrhoeae: Rapid Genotyping of Quinolone Resistance-Determining Regions in gyrA and parC Genes by Melting Curve Analysis Predicts Susceptibility,” Antimicr… [cited by applicant]
Siedner, M. et al. “Real-Time PCR Assay for Detection of Quinolone-Resistant Neisseria gonorrhoeae in Urine Samples,” Journal of Clinical Microbiology, vol. 45, No. 4, pp. 1250-1254 (Apr. 2007). [cited by applicant]
Buckley, C. et al. “Use of whole genome sequencing to investigate an increase in Neisseria gonorrhoeae infection among women in urban areas of Australia,” Scientific Reports, 8:1503, 7 pages (Jan. 24, 2018). [cited by applicant]
Gose, S. et al. “Neisseria gonorrhoeae and extended-spectrum cephalosporins in California: surveillance and molecular detection of mosaic penA,” BMC Infectious Diseases, 13:570, 9 pages (2013). [cited by applicant]
Melendez, J. et al. “Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolates in Baltimore, Maryland, 2016: The Importance of Sentinel Surveillance in the Era of Multi-Drug-Resistant Gonorrhea,” Antibiotics, 7, 77… [cited by applicant]
Papp, J. et al. “Azithromycin Resistance and Decreased Ceftriaxone Susceptibility in Neisseria gonorrhoeae, Hawaii, USA,” Emerging Infectious Diseases, vol. 23, No. 5, pp. 830-832 (May 2017). [cited by applicant]
Bolan, G. et al. “The Emerging Threat of Untreatable Gonococcal Infection,” The New England Journal of Medicine; 366; 6, pp. 485-487 (Feb. 9, 2012). [cited by applicant]
Allan-Blitz, L. et al. “A Cost Analysis of Gyrase A Testing and Targeted Ciprofloxacin Therapy Versus Recommended 2-Drug Therapy for Neisseria gonorrhoeae Infection,” Sexually Transmitted Diseases, vol. 45, No. 2 (Feb. … [cited by applicant]
Magooa, M. et al. “Determination of Neisseria gonorrhoeae susceptibility to ciprofloxacin in clinical specimens from men using a real-time PCR assay,” International Journal of Antimicrobial Agents, 42, 63-67 (2013). [cited by applicant]
Zhao, L. et al. “TaqMan Real-Time Quantitative PCR Assay for Detection of Fluoroquinolone-Resistant Neisseria gonorrhoeae,” Curr Microbiol 65: 692-695 (Sep. 2, 2012). [cited by applicant]
Trembizki, E. et al. “Further evidence to support the individualised treatment of gonorrhoea with ciprofloxacin,” Lancet Infect. Dis. 16, 1005-1006 (Sep. 2016). [cited by applicant]
Global Antibiotic Research and Development Partnership. “Gonorrhea Expert Meeting,” Drugs for Neglected Disease Initiative (Jun. 2016), 18 pages. [cited by applicant]
Dize, L. et al. “Performance of self-collected penile-meatal swabs compared to clinician-collected urethral swabs for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma g… [cited by applicant]
Wheeler, E.K., ‘Under-three minute PCR: Probing the limits of fast amplification’, published Jul. 27, 2011 by the Royal Society of Chemistry: Analyst 2011 vol. 136 pp. 3707-3712. [cited by applicant]
Moschou D., et al., ‘All-plastic, low-power, disposable, continuous-flow PCR chip with integrated microheaters for rapid DNA amplification’, Sensors and Actuators B: Chemical, vol. 199, Aug. 1, 2014, pp. 470-478. [cited by applicant]